Cell Genesys (CEGE) tumbled in pre-market trading, after announcing the termination of its VITAL-1 phase 3 trial of GVAX immunotherapy for prostate cancer based on the outcome of a futility analysis and reporting the preliminary analysis of VITAL-2 trial results.
The stock was down 41 cents just after 8:50 am ET, plummeting to 19 cents. If pre-market losses hold, the stock will open at a new low.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.